A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes

Type 2 Diabetes Mellitus Clinical Trial

— NASH  

Official title:

A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02769091
• Other study ID #: TV45478-IMM-20019
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 30, 2016
• Est. completion date: February 28, 2018

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 28, 2018
• Est. primary completion date: January 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The patient is female or male and aged 18 to 65 years, inclusive with a history of Type 2 Diabetes Mellitus (T2DM) and on stable medication for diabetes or insulin or a combination thereof for at least 3 months prior to screening.
• The patient has a NASH Activity Score (NAS) of =4, with or without evidence of fibrosis, with a score of at least 1 in steatosis and lobular inflammation the subcomponents of NAS and a hepatocyte ballooning score of at least 1 score based on historical histological evaluation of liver biopsy within 12 months prior to randomization.
• The patient has a historical diagnosis of NASH, established no more than 12 months prior to randomization based on histology (liver biopsy).
• The patient has an ALT level at screening between 45 and 105 IU/L, inclusive, for women and between 55 and 120 IU/L, inclusive for men, at one other occasion during the 24-weeks prior to screening.
• The patient has an MRI determined liver fat fraction of equal to or higher than 6% at Screening
• Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

• The patient has a history of chronic liver disease other than NASH eg, chronic or acute hepatitis, autoimmune, viral (A, B, C), genetic hepatitis, drug induced hepatotoxicity, Wilson's disease, alcoholic liver diseases, or any other non-NASH active liver disease.
• The patient has active cancer or a history of a malignant disease (except basal cell carcinoma of the skin) within 5 years prior to screening or any history of bladder cancer.
• The patient had an unstable metabolic condition (ie, with a history of weight loss or weight gain of >5 kg within 24 weeks prior to screening)
• The patient has a history of bariatric surgery within 5 years prior to screening.
• The patient has received mercaptopurine or azathioprine previously within 1 year prior to screening
• The patient has taken within 7 days prior to the first dose of study drug (or is anticipated to take during the study) anticholinergic or other drugs known to affect gastrointestinal (GI) motility, proton-pump inhibitors, or other drugs known to affect gastric acidity or use of allopurinol.
• The patient has received oral antibiotics within the last 4 weeks prior to randomization (day 1).
• The patient has received treatment within the last 30 days with any drugs known to induce or inhibit endogenous hepatic drug metabolism (eg, barbiturates, phenothiazines, cimetidine, carbamazepine) or anti-coagulant therapy (eg, heparin, warfarin, acenocoumarol).
• The patient has Type 1 Diabetes Mellitus (T1DM) or poorly controlled T2DM
• The patient has a body mass index (BMI) <25 kg/m2.
• The patient has a history of diabetic gastroparesis or has had gastric bypass surgery within the last 5 years.
• The patient has a history of pancreatitis.
• The patient has a history of persistent intestinal obstruction, bowel perforation, uncontrolled GI bleed or abdominal abscess or infection or toxic megacolon or inflammatory bowel disease (IBD)
• The patient has a history of coronary angioplasty, coronary stent placement, coronary bypass surgery, unstable angina, myocardial infarction, transient ischemic events, or stroke within 24-weeks prior to screening.
• The patient is classified as Class II-IV via New York Heart Association
• The patient has a history of drug abuse (defined as illicit drug use) or a history of excessive alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day for women or 3 alcoholic drinks per day for men) within 1 year prior to the screening visit.
• Additional criteria apply, please contact the investigator for more information

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Intervention

Drug:
• TEV-45478
80 mg (2x40mg) tablets once daily for up to 24 weeks
• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum Alanine Transaminase (ALT) levels response, defined as ALT value within reference range of <35 IU/L for women and <40 IU/L for men		Week 24
Primary	liver fat response, defined as a reduction of =6% at week 24 compared to screening by the MRI-Proton Density Fat Fraction (PDFF)		Week 24
Primary	Percentage of Participants with Adverse Events		24 weeks
Secondary	percent change from baseline in ALT		Baseline, Week 24
Secondary	percent change from baseline in ALT		Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)
Secondary	percent change from baseline in Aspartate Aminotransferase (AST)		Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)
Secondary	change from baseline in AST		Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)
Secondary	change from baseline in ALT		Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)
Secondary	Change from baseline in glycosylated hemoglobin ((HbA1c)		Baseline, Weeks 4, 12, and 24 (or early withdrawal)
Secondary	Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan)		Baseline, Week 24 (or early withdrawal)